Renagel: Advanced Phosphate Control for Chronic Kidney Disease

Renagel

Product dosage: 800mg
Package (num)	Per pill	Price	Buy
30	$4.42	$132.55 (0%)	🛒 Add to cart
60	$4.03	$265.09 $242.00 (9%)	🛒 Add to cart
120	$3.84 Best per pill	$530.19 $460.90 (13%)	🛒 Add to cart
Synonyms Sevelamero Renvela Renegal Sevelamerum Phosblock

Show more

Renagel (sevelamer hydrochloride) is a non-calcium, non-metal phosphate binder specifically formulated for the management of hyperphosphatemia in adult patients undergoing dialysis. It effectively reduces serum phosphate levels by binding dietary phosphate in the digestive tract, preventing its absorption into the bloodstream. This targeted action is critical for patients with end-stage renal disease (ESRD), as uncontrolled hyperphosphatemia is directly linked to serious cardiovascular complications and metabolic bone disease. By offering a well-tolerated alternative to traditional binders, Renagel supports long-term adherence and improved clinical outcomes in a vulnerable patient population.

Features

• Active pharmaceutical ingredient: Sevelamer hydrochloride
• Available in 400 mg and 800 mg film-coated tablets
• Non-absorbed polymer; works locally within the gastrointestinal tract
• Does not contain calcium, aluminum, or other metals
• Binds phosphate through ion-exchange and hydrogen bonding
• Requires no systemic metabolism; eliminated intact via feces
• Designed for convenient oral administration with meals

Benefits

• Effectively lowers and maintains serum phosphate within target range (3.5–5.5 mg/dL), reducing the risk of ectopic calcification.
• Minimizes the long-term bone resorption and renal osteodystrophy associated with elevated phosphorus levels.
• Decreases the incidence of cardiovascular events linked to hyperphosphatemia, such as vascular calcification and left ventricular hypertrophy.
• Avoids metal accumulation and hypercalcemia, common concerns with calcium-based or aluminum-containing binders.
• Supports patient adherence through a manageable dosing regimen that integrates seamlessly with meals.
• Contributes to overall mortality risk reduction in the dialysis population by addressing a key modifiable risk factor.

Common use

Renagel is indicated for the control of serum phosphorus in patients with chronic kidney disease on hemodialysis or peritoneal dialysis. It is prescribed when dietary phosphate restriction alone is insufficient to achieve target levels. Clinical use focuses on adult populations, though off-label use may occur in pediatric settings under specialist supervision. It is often selected for patients who cannot tolerate or have contraindications to metal-based phosphate binders, or for those requiring long-term management without risk of calcium overload.

Dosage and direction

The recommended starting dose for Renagel is 800–1600 mg taken orally with each meal, three times daily. Dosage should be individualized based on serum phosphate levels and tolerated side effects.

• Tablets must be swallowed whole with a full glass of water; do not crush or chew.
• Administer with meals or snacks to maximize binding of dietary phosphate.
• Titrate the dose in increments of 400–800 mg per meal at two-week intervals based on regular serum phosphorus measurements.
• Typical maintenance doses range from 2400 mg to 4800 mg per day, divided across three meals.
• Patients should adhere to a phosphate-restricted diet as advised by their nephrologist or dietitian.

Precautions

• Use with caution in patients with dysphagia, swallowing disorders, or severe gastrointestinal motility impairments, due to risk of esophageal or bowel obstruction.
• Monitor for signs of fecal impaction or constipation, especially in elderly patients or those with history of bowel surgery.
• Serum calcium, bicarbonate, and chloride levels should be periodically assessed due to potential mild metabolic acidosis.
• Not recommended for use in patients not on dialysis, or in those with hypophosphatemia.
• Pregnancy Category C: Use only if potential benefit justifies potential risk to the fetus.
• Vitamin D and other fat-soluble vitamin levels should be monitored; supplementation may be required.

Contraindications

• Hypersensitivity to sevelamer hydrochloride or any component of the formulation.
• Bowel obstruction or history of major gastrointestinal surgery affecting motility.
• Hypophosphatemia.
• Patients not receiving dialysis.

Possible side effect

Common side effects (may affect up to 1 in 10 users):

• Nausea, vomiting, diarrhea, or abdominal discomfort
• Dyspepsia, flatulence, constipation

Less common side effects (may affect up to 1 in 100 users):

• Fecal impaction or intestinal obstruction (rare but serious)
• Pruritus, rash
• Headache

Serious but rare adverse reactions:

• Bowel perforation (extremely rare, usually in predisposed patients)
• Severe metabolic acidosis

Drug interaction

• Renagel may decrease the absorption of concomitantly administered oral medications. Administer other drugs at least 1 hour before or 3 hours after Renagel.
• Known interactions include: ciprofloxacin, levothyroxine, and mycophenolate mofetil.
• Use with caution alongside drugs with a narrow therapeutic index (e.g., digoxin, warfarin). Monitor levels closely.
• May bind to fat-soluble vitamins (A, D, E, K); supplementation and monitoring advised.

Missed dose

If a dose is missed, the patient should take it with the next meal. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Do not double the dose to make up for a missed administration.

Overdose

There is no known specific antidote for Renagel overdose. Since the drug is not absorbed systemically, overdose would likely manifest as severe gastrointestinal complaints (e.g., significant constipation, obstruction). Treatment is symptomatic and supportive. In severe cases, endoscopic or surgical intervention may be required to relieve bowel obstruction.

Storage

• Store at room temperature (15–30°C or 59–86°F).
• Keep in the original container, tightly closed, and protect from moisture.
• Keep out of reach of children and pets.
• Do not use beyond the expiration date printed on the packaging.

Disclaimer

This information is intended for educational and professional reference only and does not replace clinical judgment or personalized medical advice. Prescribing and usage must be guided by a qualified healthcare professional familiar with the patient’s full medical history. Always refer to the official prescribing information for complete details, warnings, and contraindications.

Reviews

Renagel is generally well-regarded in nephrology circles for its efficacy and safety profile. Clinical studies and meta-analyses consistently support its role in phosphate management, particularly in avoiding calcium loading. Many clinicians appreciate its utility in complex cases where traditional binders are unsuitable. Patient feedback often highlights gastrointestinal tolerability as a key advantage over older agents, though individual experiences with side effects vary. Long-term users report improved lab values and quality of life when adherence is maintained.